Extranuclear coactivator signaling confers insensitivity to tamoxifen.

ABSTRACT:

Purpose

Tamoxifen is one of many standard therapeutic options currently available for estrogen receptor-alpha-positive breast cancer patients. Emerging data have suggested that levels of estrogen receptor coregulatory proteins play a significant role in acquiring resistance to antiestrogen action. It has been suggested that high levels of estrogen receptor coactivators and its mislocalization may enhance the estrogen agonist activity of tamoxifen and contribute to tamoxifen resistance.

Experimental design

In an effort to understand the impact of nongenomic signaling and its contribution to hormone resistance in a whole-animal setting, we generated a transgenic mouse expressing a cytoplasmic version of proline-, glutamic acid-, and leucine-rich protein-1 (PELP1) mutant defect

SUBMITTER: Kumar R 

PROVIDER: S-EPMC2756964 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature